BIOPHYTIS PRESENTS ITS DEVELOPMENT PROGRAMS IN OBESITY AND SARCOPENIA AT THE ICFSR CONFERENCE

Press Release

BIOPHYTIS PRESENTS ITS DEVELOPMENT PROGRAMS IN OBESITY AND SARCOPENIA AT THE ICFSR CONFERENCE

Paris (France), Cambridge (Massachusetts, USA), March 13, 2026 – 07:30 a.m, CET – Biophytis SA (Euronext Growth Paris: ALBPS) (“Biophytis” or the “Company”), a pioneer in developing transformative therapies targeting longevity, announces that it participated in the Intrinsic Capacity, Frailty and Sarcopenia Research Conference for Healthy Longevity (ICFSR), held from March 10 to 12, 2026 in Washington, DC (United States).

The ICFSR international conference (https://frailty-sarcopenia.com/) is a leading international scientific event dedicated to advancing clinical research on frailty, sarcopenia and, more broadly, the mechanisms of aging. It brings together researchers, clinicians and industry stakeholders to accelerate clinical trials on frailty, sarcopenia, intrinsic capacity and healthy longevity through nutrition, exercise, geroscience and artificial intelligence.

In this context, Dr. Cendrine Tourette, Director of Clinical Programs at Biophytis, delivered an oral presentation entitled “BIO101 (20-hydroxyecdysone) in Obesity: towards Phase 2 program”, dedicated to the clinical development of BIO101 in obesity, and also participated in the Biotech Showcase, which provided an opportunity to present the latest advances in the SARA program in sarcopenia.

Biophytis’ participation in ICFSR 2026 reflects the Company’s ongoing commitment to the international scientific community to advance clinical research in age-related diseases and contribute to the development of innovative therapeutic solutions supporting healthy longevity.

* * *

About BIOPHYTIS

Biophytis SA is a clinical-stage biotechnology company focused on developing drug candidates for age‑related diseases. BIO101 (20-hydroxyecdysone), our lead drug candidate, is a small molecule in development for muscular diseases (sarcopenia, Phase 3 ready to start) and metabolic disorders (obesity, Phase 2 ready to start). The company is headquartered in Paris, France, with subsidiaries in Cambridge, Massachusetts, USA, and Brazil. The Company’s ordinary shares are listed on Euronext Growth Paris (ALBPS - FR001400OLP5) and its ADS (American Depositary Shares) are listed on the OTC market (BPTSY - US 09076G401). For more information, visit www.biophytis.com.

Disclaimer

This press release contains forward-looking statements. Forward-looking statements include all statements that are not historical facts. In some cases, you can identify these forward-looking statements by the use of words such as "outlook," "believes," "expects," "potential," "continues," "may," "will," "should," "could," "seeks," "predicts," "intends," "trends," "plans," "estimates," "anticipates" or the negative version of these words or other comparable words. Such forward-looking statements are based on assumptions that Biophytis considers to be reasonable. However, there can be no assurance that the statements contained in such forward-looking statements will be verified, which are subject to various risks and uncertainties. The forward- looking statements contained in this press release are also subject to risks not yet known to Biophytis or not currently considered material by Biophytis. Accordingly, there are or will be important factors that could cause actual outcomes or results to differ materially from those indicated in these statements. Please also refer to the "Risk and uncertainties the Company is to face" section from the Company’s 2023 Financial Report available on BIOPHYTIS website (www.biophytis.com) and as exposed in the "Risk Factors" section of form 20-F as well as other forms filed with the SEC (Securities and Exchange Commission, USA). We undertake no obligation to publicly update or review any forward-looking statement, whether because of new information or otherwise, except as required by law.

Biophytis Contacts

Investor Relations
Investors@biophytis.com

Media contacts
Antoine Denry: antoine.denry@taddeo.fr – +33 6 18 07 83 27
Nizar Berrada : nizar.berrada@taddeo.fr - +33 6 38 31 90 50